Paul Hofman is Professor of pathology since 1995. He is the head of the research team at the Inserm 1081/UMR CNRS 7284 (IRCAN), located at the Comprehensive Cancer Center Antoine Lacassagne, Nice. The main topic of this team is related to lung cancer pathophysiology and circulating biomarkers discovery. He is the head of the Hospital-related Biobank (BB-0033-00025) and of the Laboratory of Clinical and Experimental Pathology (LPCE) at Pasteur Hospital (University of Nice Côte d’Azur). He is the director of the IHU RespirERA and the director of the FHU OncoAge (www.oncoage.org) He is member of the Labex Signalife, the BBMRI-ERIC, the ESBB, the BRIF consortium and of the National Infrastructure Biobank (Paris, France).
Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, Nice
Laboratory of Clinical and Experimental Pathology and Liquid Biopsy Laboratory, Pasteur Hospital, Nice
University Hospital Institute RespirERA; Nice, France;
University Hospital Federation OncoAge, CHU de Nice, Université Côte d’Azur, Nice
Institute for Research on Cancer and Ageing, Nice (IRCAN), INSERM U1081/UMR CNRS 7284, Antoine Lacassagne Cancer Center of Nice
Paul Hofman, Program Director, M.D., Ph.D., Director IHU RespirERA
Paul Hofman is Professor of Pathology at the University Côte d’Azur, Nice France. He graduated in Nice and in Paris. He was a fellow in Pathology at the Brigham and Women’s Hospital (Harvard Medical School, Boston) and at the Max Planck Institute (Tubingen, Germany). He was awarded a PhD in Cell Biology (University of Montpellier, France). He is the Head of the Laboratory of Clinical and Experimental Pathology, Louis Pasteur Hospital, Nice. He is the Director of the University Hospital Federation, FHU OncoAge (www.oncoage.org) and of the Hospital-related Biobank (BB-0033-00025, http://www.biobank-cotedazur.fr/en/). He was the Director of the MSc Biobanks at the ESTBB in Lyon University from 2012 to 2016, then of of the MSc Biobanks and Complex Data Management at the University Côte d’Azur from 2017 to 2021. He is the Director of the Research Team 4 (Inserm 10181/UMR CNRS 7284 - IRCAN center, www.ircan.org) aiming on determining the spectrum of genetic, non-genetic, and cellular events in lung cancer to better characterize the underlying mechanisms associated with non-therapeutic response. The main interest of his research is to identify biomarkers for non-response to immunotherapies and/or targeted therapies, and to improve therapeutic response with the next-generation combination of molecules. He is the Director of the Liquid Biopsy Center in Nice which has been selected to be a European Expert Center in LBx. He is a member of the Royal Academy of Medicine (Brussels) and an executive board member of the European Liquid Biopsy Society. He is the Chair of the Pulmonary Pathology Committee of the European Society of Pathology. He is member of the Pathology Committee of the IASLC and the Co-Chair of the Molecular Pathology Working Group at the IASLC. He published more than 600 articles (h-index: 80). Since May 2024 he is the Director of the new Institut Hospitalo-Universitaire (IHU) RespirERA (https://ihu-respirera.fr) in Nice.
dagher
Pedagogic Team
Doctor Georges DAGHER
Georges Dagher is currently an Emeritus Senior Researcher at the National Institute for Health and Research, (Inserm), Paris; Visiting Professor at Faculty of Medicine, Milano-Bicocca University, Italy; He is also the CEO of a private society, Paradigm 66.
He was an Honorary professor at Stem Laboratory, Chinese Academy of Sciences, Beijing; and also a visiting Professor at Graz Medical University, Austria.
Georges Dagher accomplished most of his career in pathophysiological and clinical research at Necker Hospital (1979-1984), College de France (1985-1993) and Faculty of medicine Broussais-Hotel Dieu (1994-2004). He joined the Physiological Laboratory (Cambridge, UK) for a postdoctoral fellowship (1983-1985) and was a visiting researcher to Biophysics & Physiological laboratory (Harvard Medical School, Boston, US, 1982, 1984), Cleveland Clinic (1986) and Farmitalia (1982). He published about 100 papers in international peer-reviewed journals on hypertension, arterial hypertrophy, obesity and lipid metabolism, manic depression, renal physiology and transmembrane ion transport.
He was the Director of the BIOBANQUES infrastructure, a French infrastructure that networks 85 biobanks and the vice chair of BBMRI-ERIC a pan European Infrastructure that networks more than 500 biobanks in Europe. Prior to this role, He acted as the Director of clinical research infrastructures at Inserm and Deputy Director of the department of clinical research at the Public Health Institute, Inserm, France.
He is the Convenor of a Working Group Biobanking and Biological Ressources at the ISO Technical Committee “Biotechnology” (ISO/TC 276) and member of several Technical Committees at International Standard Organisation: Medical laboratory (ISO/TC 212), Food Products (ISO/TC 34); Health informatics (ISO/TC 215). He actively contributed to the publication of 40 International standards related to the biomedical field, laboratory analysis and testing, and health informatics. He is also a reference expert to more than 200 standards in these fields (work in in progress). He is also affiliated to ISO CASCO and ISO REMCO.
Previously, he chaired the elaboration of the NF S96-900 French standard for biobanks (2008) and contributed to the OECD best practice guidelines for biological resource centres and the OECD guidelines on human biobanks and genetic databases (2006-2009).
He was a delegate of several French institutions to European and international committees (OECD, ESF, ERA, ALLEA, EASAC…) and of a number of expert committees focusing on issues related to biobanks within Europe and internationally. He was an expert to the Austrian Federal ministry of science and research (BMWF) and Institut de Recherche sur le Cancer (Maroc), National biobank infrastructure in Italy and Austria and was an expert to the Flemish ministry of research, Quebec "Fond Scientifique de la Recherche", Swiss National Science Foundation.
bruno
Pedagogic Team
Doctor Bruno CLEMENT
After completing a PhD in cellular and molecular biology, Bruno Clément spent a post-doc period at the NIH in Bethesda (USA). In 1985, he was recruited by Inserm in the “Liver research unit” in Rennes. In 1992, he became research director of the “Microenvironment and Tumor Progression” team at Inserm U-620. Head of the Inserm “Liver, Metabolism and Cancer” unit in 2010, he was appointed director of the “Nutrition, Metabolism and Cancer” Institute in 2017 (Inserm-Inrae-University of Rennes). Most of his work focuses on liver pathophysiology, chronic liver diseases, and hepatic carcinogenesis. His main scientific contributions include the characterization of hepatic fibrosis and its cellular origin; the reversibility of hepatic fibrosis; the role of the microenvironment and tissue remodeling in hepatocyte function, in fibrosis/cirrhosis, and in the onset and progression of hepatocellular carcinoma; cell engineering: 2D and 3D (organoids), bioartificial liver; selective cell irradiation in the treatment of hepatocellular carcinoma. Counselor at the Ministry of Research in 1998, then Deputy Director of the Bioengineering Department in 2000, Bruno Clément participated in the implementation of the Innovation Act of July 1999 by launching incentives for the development of biotechnologies in the field of health and the national program for biological resource centers (incentives, parliamentary report, revision of bioethics laws in 2004, chairmanship of the National Advisory Committee for BRCs). He was member of several international committees on biobanks: OECD (head of delegation), 7th PCRDT, NIH, WHO, Council of Europe, International Network of Pasteur Institutes, AFNOR, ISO. From 2003 to 2007, Bruno Clément was advisor to the Director General of Inserm for biotechnologies and biobanks, and scientific director of Inserm-Transfert. He was scientific director of the National Biobank Infrastructure from 2011 to 2016. Bruno Clément is currently member of the Inserm Ethics Committee (IRB-CEEI) and full member of the French National Academy of Medicine.
